FDA Accepts Summit Therapeutics' BLA for Ivonescimab in NSCLC Treatment
Event summary
- The FDA accepted Summit Therapeutics' Biologics License Application (BLA) for ivonescimab in combination with chemotherapy for EGFR-mutated NSCLC post-TKI therapy.
- The Prescription Drug User Fee Act (PDUFA) goal action date is November 14, 2026.
- The BLA submission is based on results from the Phase III HARMONi trial.
- Ivonescimab is a novel bispecific antibody combining PD-1 blockade and anti-angiogenesis effects.
The big picture
Summit Therapeutics' BLA acceptance marks a critical step in bringing a novel bispecific antibody to market for a specific NSCLC patient population. The FDA's review process will be closely watched, as success could position ivonescimab as a competitive option in the oncology space. The strategic partnership with Akeso Inc. underscores the global clinical development efforts underway.
What we're watching
- Regulatory Success
- Whether the FDA's review will identify major deficiencies that could delay or prevent approval.
- Clinical Efficacy
- How the results of the HARMONi trial will compare to existing treatments in the EGFR-mutated NSCLC space.
- Market Potential
- The pace at which Summit can commercialize ivonescimab if approved, given its first-in-class status.
Related topics